Insulin-like growth factors I and II in healthy women with and without established osteoporosis.
We measured serum concentrations of insulin-like growth factors I and II (IGF-I and IGF-II) by radioimmunoassay in 107 healthy women aged 28-78 years and in 116 women with established osteoporosis. The women with established osteoporosis were randomized to a 1-year double-blind, placebo-controlled treatment with continuous estrogen/progestogen, anabolic steroids, salmon calcitonin or placebo and the IGFs were measured every 6 months. Women less than 35 years of age had 29% higher levels of IGF-I (p < 0.001) as compared to women above that age. For women more than 35 years of age, we found no correlation between IGF-I and age (r = 0.02). Correspondingly, we found no significant changes in serum IGF-I in 10 women, who were followed with serial measurements of IGFs every 3 months from 2 years before to 1 year after menopause; IGF-II revealed no correlation with age (r = 0.04). In the group of 116 women with established osteoporosis, IGF-I was 30% lower (p < 0.01) as compared to a group of 19 height-, weight- and age-matched nonfractured women (mean age 64 years). The IGF-II levels were equal in the two groups. Over the 1-year therapeutic intervention period, an increase in IGF-I of 13-15% (p < 0.05) was seen in the nandrolone decanoate-treated group. The same tendency was seen for hormone replacement therapy, although it was not significant. In conclusion, the serum level of IGF-I is high in young women, when peak bone mass is attained, and low in postmenopausal women with established osteoporosis.
Ravn
P
P
Center for Clinical & Basic Research, Ballerup, Denmark.
Overgaard
K
K
Spencer
E M
EM
Christiansen
C
C
D000328:Adult; D000368:Aged; D000375:Aging / Q000097:blood; D015415:Biomarkers / Q000097:blood; D015519:Bone Density; D001861:Bone Regeneration; D002116:Calcitonin / Q000627:therapeutic use; D004311:Double-Blind Method; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D007335:Insulin-Like Growth Factor II / Q000378:metabolism*; D016014:Linear Models; D008875:Middle Aged; D009277:Nandrolone / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077603:Nandrolone Decanoate; D015663:Osteoporosis, Postmenopausal / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D011863:Radioimmunoassay; D012016:Reference Values
D015415:Biomarkers; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; D009277:Nandrolone; D002116:Calcitonin; D000077603:Nandrolone Decanoate